(Reuters) – An Oklahoma judge on Monday will decide whether Johnson & Johnson (JNJ.N) should be held liable in a $17 billion lawsuit alleging the drugmaker’s marketing practices fueled the opioid epidemic by flooding the market with painkillers.

The case brought by Oklahoma Attorney General Mike Hunter was the first to go to trial out of thousands of lawsuits filed by state and local governments against opioid manufacturers and distributors.

Judge Thad Balkman, of Cleveland County District Court in Norman, Oklahoma, is scheduled to announce his decision from the bench at 4 p.m. EDT (2000 GMT).

Hunter is seeking to make J&J pay more than $17 billion to help the state address the epidemic for the next 30 years through addiction treatment and prevention programs.

The trial came after Oklahoma resolved claims against OxyContin maker Purdue Pharma LP in March for $270 million and against Teva Pharmaceutical Industries Ltd (TEVA.TA) in May for $85 million, leaving J&J as the lone defendant.

The litigation is being closely watched by plaintiffs in about 2,000 opioid lawsuits pending before a federal judge in Ohio who has been pushing for a settlement ahead of an October trial.

Some plaintiffs’ lawyers have compared the opioid cases to litigation by states against the tobacco industry that led to a $246 billion settlement in 1998.

Opioids were involved in almost 400,000 overdose deaths from 1999 to 2017, according to the U.S. Centers for Disease Control and Prevention. Since 2000, some 6,000 Oklahomans have died from opioid overdoses, according to the state’s lawyers.

During a seven-week non-jury trial, lawyers for the state of Oklahoma argued that J&J carried out a years-long marketing campaign that minimized the addictive painkillers’ risks and promoted their benefits.

The state’s lawyers called J&J an opioid “kingpin” and argued that its marketing efforts created a public nuisance as doctors over-prescribed the drugs, leading to a surge in overdose deaths in Oklahoma.

J&J has denied wrongdoing. The drugmaker in court said its marketing claims had scientific support and that its painkillers, Duragesic and Nucynta, made up a tiny fraction of opioids prescribed in Oklahoma.

The company said in a statement that since 2008, its painkillers accounted for less than 1 percent of the U.S. market, including generics.

Lawyers for New Jersey-based J&J have said the case rests on a “radical” interpretation of the state’s public nuisance law.

J&J said on Monday that the state’s attempt to use public nuisance law to resolve a “complex social problem” was “misguided and legally unsustainable.”

“Not once did the state identify a single Oklahoma doctor who was misled by a single Janssen statement, nor did it prove that Janssen misleadingly marketed opioids or caused any harm in Oklahoma,” John Sparks, Oklahoma counsel for Johnson & Johnson, said in a statement. Janssen Pharmaceuticals is the healthcare conglomerate’s primary prescription drugs unit.

J&J said it has not set aside a litigation reserve to pay potential damages and that its policy is to only set aside a reserve once a loss is “probable and can be reasonably estimated.”

Source: Read Full Article